Fernández DE, Fernández JE, Moreno MI, Moreno MM

Idioma: Español
Referencias bibliográficas: 51
Paginas: 533- 546
Archivo PDF: 351.79 Kb.

RESUMEN

Las pruebas de función hepática se emplean para detectar, diagnosticar específicamente, estimar la severidad, y monitorear el curso de la enfermedad hepática. La interpretación efectiva del panel de función hepática requiere un conocimiento de la fisiopatología subyacente y las características de las pruebas del panel. Utilizando un enfoque esquemático, se clasifican las alteraciones hepáticas en dos grandes categorías: 1) necrosis celular y 2) colestasis, y aplicando el panel de función hepática recomendado por The National Academy of Clinical Biochemistry y la American Association for the Study of Liver Diseases, se interpretan las principales pruebas y su utilidad para evaluar inicialmente las enfermedades hepáticas sospechadas o conocidas de acuerdo con su capacidad para detectar daño celular, falta de permeabilidad de vías biliares, metabolismo aniónico orgánico y síntesis proteica. Finalmente se hacen unas recomendaciones para la interpretación del panel depruebas dentro del contexto clínico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. 1.Thapa BR, Walia A. Liver function tests and their interpretation. Indian J Pediatr 2007; 74: 663-671.

2. Henry JB. El laboratorio en el diagnóstico clínico: homenaje a Todd-Sanford & Davidson. Marban, 10a edición. Madrid; 2005.

3. Wallach J. Enfermedades hepatobiliares y pancreáticas. In Interpretación clínica de las pruebas de laboratorio. Masson, 4ta edición. 2003; 255-338.

4. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem 2000; 46: 2027-2049.

5. Burke MD. Liver function: test selection and interpretation of results. Clin Lab Med 2002; 22: 377-390.

6. Knight JA. Liver function tests: their role in the diagnosis of hepatobiliary diseases. J Infus Nurs 2005; 28: 108-117.

7. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000; 46: 2050-2068.

8. Burke MD. Liver function. Hum Pathol 1975; 6: 273-286.

9. Kamath PS. Clinical approach to the patient with abnormal liver test results. Mayo Clin Proc 1996; 71: 1089-1094; quiz 1094-1085.

10. Gopal DV, Rosen HR. Abnormal findings on liver function tests. Interpreting results to narrow the diagnosis and establish a prognosis. Postgrad Med 2000; 107: 100-102, 105-109, 113-104.

11. Pincus MR, Tierno P, Dufour DR. Evaluation of liver function. In Henry’s clinical diagnosis and management by laboratory methods, McPherson, Pincus, MR. 21st edition, Saunders Elsevier; China. 2007; 263-278.

12. Kew MC. Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet 2000; 355: 591-592.

13. Johnston DE. Special considerations in interpreting liver function tests. Am Fam Physician 1999; 59: 2223-2230.

14. Betro MG. Significance of increased alkaline phosphatase and lactate dehydrogenase activities coincident with normal serum bilirubin. Clin Chem 1972; 18: 1427-1429.

15. Tolaymat N, de Melo MC. Benign transient hyperphosphatasemia of infancy and childhood. South Med J 2000; 93: 1162-1164.

16. Structure, formation, and sources of bilirubin and its transport in plasma. Semin Liver Dis 1994; 14: 325-330.

17. Hayden K, van Heyningen C. Measurement of total protein is a useful inclusion in liver function test profiles. Clin Chem 2001; 47: 793-794.

18. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938.

19. McFarlane IG. Lessons about antibodies in autoimmune hepatitis. Lancet 2000; 355: 1475-1476.

20. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335: 1570-1580.

21. Neuberger J. Primary biliary cirrhosis. Lancet 1997; 350: 875-879.

22. Saab S, Martin P. Tests for acute and chronic viral hepatitis. Finding your way through the alphabet soup of infection and superinfection. Postgrad Med 2000; 107: 123-126, 129-130.

23. Sacher RA, Peters SM, Bryan JA. Testing for viral hepatitis. A practice parameter. Am J Clin Pathol 2000; 113: 12-17.

24. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.

25. Fabris P, Fleming VM, Giordani MT, Barnes E. Acute hepatitis C: clinical aspects, diagnosis, and outcome of acute HCV infection. Curr Pharm Des 2008; 14: 1661-1665.

26. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008; 23: 512-520.

27. Cayley WE, Jr. Haemochromatosis. Bmj 2008; 336: 506.

28. Morrison ED, Kowdley KV. Genetic liver disease in adults. Early recognition of the three most common causes. Postgrad Med 2000; 107: 147-152, 155, 158-149.

29. Gow PJ, Smallwood RA, Angus PW, Smith AL, Wall AJ, Sewell RB. Diagnosis of Wilson’s disease: an experience over three decades. Gut 2000; 46: 415-419.

30. Mak CM, Lam CW. Diagnosis of Wilson’s disease: a comprehensive review. Crit Rev Clin Lab Sci 2008; 45: 263-290.

31. Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol 2008; 103: 2136-2141; quiz 2142.

32. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. Cmaj 2005; 172: 367-379.

33. Musana KA, Yale SH, Abdulkarim AS. Tests of liver injury. Clin Med Res 2004; 2: 129-131.

34. Sakka SG. Assessing liver function. Curr Opin Crit Care 2007; 13: 207-214.

35. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342: 1266-1271.

36. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. Bmj 2004; 328: 983.

37. Kaplan MM. Alanine aminotransferase levels: what’s normal? Ann Intern Med 2002; 137: 49-51.

38. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.

39. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163: 218-224.

40. Beckingham IJ, Ryder SD. ABC of diseases of liver, pancreas, and biliary system. Investigation of liver and biliary disease. Bmj 2001; 322: 33-36.

41. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339: 1217-1227.

42. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-739.

43. Vishwanath RL. Enfermedad hepática. In Fisiopatología médica. Manual moderno. 4ta edición. 2003; 403-443.

44. Wang X, Chowdhury JR, Chowdhury NR. Bilirubin metabolism: Applied physiology. . Current Paediatrics 2006; 16: 70-74.

45. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218.

46. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-1654.

47. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007; 117: 539-548.

48. American Medical Association. Current procedural terminology for pathology and laboratory medicine. 4ta. edición. AMA Press; Chicago. 2001.

49. Quesada A. Diagnóstico de laboratorio: principales pruebas bioquímicas y de laboratorio. 1ra edición, 2003.

50. Ruiz-Reyes G. Fundamentos de interpretación clínica de los exámenes de laboratorio. 1era edición, 2004.

51. Nicoll D, McPhee S, Pignone M. Manual de pruebas diagnósticas. Manual moderno. 4ta edición, 2004.